Publication | Open Access

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial

Metabolic SyndromeType 1Diabetes ManagementHealth PolicyCardiovascular DiseaseDiabetesPharmacotherapyDiabetes MellitusPublic HealthMedicinePhase 3Week Results